CytoAgents

CytoAgents is a clinical-stage biotechnology company developing innovative pharmaceutical products for life-threatening conditions. Its lead asset, CTO1681, is an oral small molecule immune modulator designed to prevent and treat Cytokine Release Syndrome and other inflammatory conditions through selective prostacyclin/prostaglandin receptor signaling.